Breaking News Instant updates and real-time market news.

GE

General Electric

$12.01

-0.08 (-0.66%)

, FB

Facebook

$159.79

-2.65 (-1.63%)

11:14
10/02/18
10/02
11:14
10/02/18
11:14

Fly Intel: Today's top analyst calls on Wall Street

Check out today's top analyst calls from around Wall Street, compiled by The Fly. GE UPGRADED AT RBC, WOLFE: RBC Capital analyst Deane Dray upgraded General Electric (GE) to Outperform from Sector Perform and raised his price target for the shares to $15 from $13. The analyst believes a floor has been put in the shares following news of Larry Culp being named Chairman and CEO. Additionally, GE was upgraded to Outperform from Peer Perform at Wolfe Research. DEUTSCHE SEES HEIGHTENED RISKS TO FACEBOOK ESTIMATES: After attending the first day of AdWeek, Deutsche Bank analyst Lloyd Walmsley sees heightened risk to the Q3, Q4 and 2019 consensus estimates for Facebook (FB). The analyst said he's starting to hear more cautious feedback and that Facebook seems on the defensive, particularly following last week's data breach disclosure. Walmsley, however, continues to view Facebook as attractively valued and kept a Buy rating on the shares with a $205 price target. JPMORGAN ADDS WEIGHT WATCHERS TO FOCUS LIST: JPMorgan analyst Christina Brathwaite added Weight Watchers (WTW) to her firm's America's Analyst Focus while keeping an Overweight rating on the shares with a $120 price target. The stock's 30% pullback from its peak on June 20 presents a "compelling entry point for investors who missed the stock's appreciation the first time around," Brathwaite said. Despite the post-earnings selloff, the analyst believes the Q2 print was actually indicative that Weight Watchers' growth story remains on track. Further, she believes the changes announced last week, including its new rewards program, as well as the company's Invite a Friend program, will help drive member recruitment and retention going forward. AMBEV DOUBLE DOWNGRADED BY UBS: UBS analyst Alan Alanis double downgraded Ambev (ABEV) to Sell from Buy and lowered his price target for the shares to R$17 from R$23. AmBev trades at a 25% higher valuation than parent company AB InBev (BUD), which is unwarranted, Alanis believes. He believes Ambev shares at current levels are more than pricing in the company's favorable outlook. Further, he expects consensus estimates to come down due to a tougher competitive environment, a "tepid" Brazilian economic recovery and currency headwinds. DEUTSCHE DOWNGRADES METAL STOCKS: Deutsche Bank analyst Jeremy Kliewer downgraded Century Aluminum to Hold from Buy and lowered his price target for the shares to $15 from $20, stating that Century's margins could remain pressured for longer due to alumina supply disruptions. Meanwhile, Deutsche's Chris Terry downgraded Reliance Steel (RS) to Hold from Buy and lowered his price target for the shares to $90 from $100, and downgraded U.S. Steel (X) to Hold from Buy and lowered his price target for the shares to $35 from $47. The analyst said his view on the steel sector is "moderating post peak pricing." Most positive data points and catalysts have now largely played out, Terry believes.

GE

General Electric

$12.01

-0.08 (-0.66%)

FB

Facebook

$159.79

-2.65 (-1.63%)

ABEV

Ambev

$4.64

0.035 (0.76%)

BUD

AB InBev

$85.58

-0.96 (-1.11%)

CENX

Century Aluminum

$11.84

-0.235 (-1.95%)

RS

Reliance Steel

$85.21

-0.82 (-0.95%)

X

U.S. Steel

$29.22

-1.02 (-3.37%)

WTW

Weight Watchers

$74.15

1.43 (1.97%)

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 28

    Oct

  • 30

    Oct

  • 02

    Nov

  • 07

    Nov

GE General Electric
$12.01

-0.08 (-0.66%)

10/02/18
RBCM
10/02/18
UPGRADE
Target $15
RBCM
Outperform
General Electric upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Deane Dray upgraded General Electric to Outperform and raised his price target for the shares to $15 from $13. The analyst believes a floor has been put in the shares following news of Larry Culp being named Chairman and CEO.
10/02/18
SBSH
10/02/18
NO CHANGE
SBSH
Buy
GE management change bigger than $23B impairment, says Citi
Yesterday's announcement of Larry Culp being named Chairman and CEO is a "new beginning" for General Electric, Citi analyst Andrew Kaplowitz tells investors in a research note. The analyst says that while the Power business is "dramatically worse" than he thought, a "proven outside leader" can immediately accelerate the pace of change and execution. Management change is bigger and more forward looking than the $23B non-cash impairment the company will take on its Power business, Kaplowitz contends. The analyst keeps a Buy rating on General Electric.
10/02/18
WOLF
10/02/18
UPGRADE
WOLF
Outperform
General Electric upgraded to Outperform from Peer Perform at Wolfe Research
10/02/18
10/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Discover (DFS) upgraded to Overweight from Neutral at JPMorgan with analyst Richard Shane saying the company appears on track to execute a "soft landing" as loan growth stabilizes. 2. At Home Group (HOME) upgraded to Buy from Neutral at Goldman Sachs with analyst Matthew Fassler saying recent sales misses, tariff concerns, and macro data have created investor concerns and a "steep discount" in the shares relative to other growth retailers. 3. Nestle (NSRGY) upgraded to Buy from Hold at Jefferies with analyst Martin Deboo saying he's more bullish on the new CEO and the shares into the second half of the year. 4. Urban Outfitters (URBN) upgraded to Buy from Neutral at B. Riley FBR with analyst Susan Anderson saying she expects high consumer confidence to support strong same-store-sales for Urban and she views the shares as undervalued. 5. General Electric (GE) upgraded to Outperform from Sector Perform at RBC Capital with analyst Deane Dray saying he believes a floor has been put in the shares following news of Larry Culp being named Chairman and CEO. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FB Facebook
$159.79

-2.65 (-1.63%)

10/02/18
DBAB
10/02/18
NO CHANGE
Target $205
DBAB
Buy
Deutsche Bank sees heightened risk to consensus Facebook estimates
After attending the first day of AdWeek, Deutsche Bank analyst Lloyd Walmsley sees heightened risk to the Q3, Q4 and 2019 consensus estimates for Facebook. The analyst says he's starting to hear more cautious feedback and that Facebook seems on the defensive, particularly following last week's data breach disclosure. Walmsley, however, continues to view Facebook as attractively valued and keeps a Buy rating on the shares with a $205 price target. The stock in early trading is down 93c to $161.51.
10/01/18
CHLM
10/01/18
NO CHANGE
Target $19
CHLM
Sell
Applied Optoelectronics price target lowered to $19 from $28 at Craig-Hallum
Craig-Hallum analyst Richard Shannon lowered his price target for Applied Optoelectronics (AAOI) to $19 from $28, citing the lower guide on quality issues, likely at number one customer. The analyst believes the specific customer is Facebook (FB), where his checks indicate competitor Intel (INTC) is poised to ramp production and gain share. Since data center customers' value supply chain execution nearly as much as quality and price, Shannon worries that this action may cause Facebook to allocate share increasingly to Intel and Innolight. The analyst reiterates a Sell rating on Applied Optoelectronics shares.
10/01/18
DADA
10/01/18
NO CHANGE
Target $36
DADA
Buy
Applied Optoelectronics price target lowered to $36 from $54 at DA Davidson
DA Davidson analyst Mark Kelleher lowered his price target on Applied Optoelectronics (AAOI) to $36 after its negative Q3 pre-announcement, stating that at its projected revenue rate it will be difficult for the company to show a profit. The analyst notes that the company's quality control issue was related to 25G lasers that led to suspended shipments of transceivers to a "single customer", adding that the entity was likely Facebook (FB) with whom Applied Optoelectronics has a $125M transceiver contract. Despite the pre-announcement, Kelleher keeps his Buy rating on the shares longer term, saying that as "one of the leading providers of optical networking technology to the datacenter and cable TV markets", the company is " well positioned to benefit from the growing dominance of 'hyperscale' data centers".
09/26/18
BOFA
09/26/18
NO CHANGE
Target $205
BOFA
Buy
BofA/Merrill says Facebook changes may signal accelerated Instagram monetization
Following news that Instagram founders Kevin Systrom and Mike Krieger are leaving Facebook, BofA Merrill Lynch analyst Justin Post said some will express valid concerns that the leadership change is a risk to Instagram culture and usage growth. However, he noted that Facebook purchased Instagram over five years ago and does not anticipate a near-term financial impact. He also thinks acceleration of Instagram monetization is possible and believes investors may reconsider the potential value in Messenger and WhatsApp. Post maintains a Buy rating and $205 price target on Facebook shares.
ABEV Ambev
$4.64

0.035 (0.76%)

10/02/18
UBSW
10/02/18
DOWNGRADE
UBSW
Sell
Ambev downgraded to Sell from Buy at UBS
UBS analyst Alan Alanis double downgraded Ambev (ABEV) to Sell from Buy and lowered his price target for the shares to R$17 from R$23. AmBev trades at a 25% higher valuation than parent company AB InBev (BUD), which is unwarranted, Alanis tells investors in a research note. He believes Ambev shares at current levels are more than pricing in the company's favorable outlook. Further, he expects consensus estimates to come down due to a tougher competitive environment, a "tepid" Brazilian economic recovery and currency headwinds.
06/18/18
JPMS
06/18/18
DOWNGRADE
Target $5.6
JPMS
Neutral
Ambev downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Lucas Ferreira downgraded Ambev to Neutral and lowered his price target for the shares to $5.60 from $6.50. The analyst sees reduced earnings visibility amid domestic growth deceleration and increased competition.
07/27/18
LEHM
07/27/18
UPGRADE
Target $6
LEHM
Overweight
Ambev upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Benjamin Theurer upgraded Ambev to Overweight while lowering his price target for the shares to $6 from $7. The analyst expects the company's expenses to normalize now that the World Cup has passed and is incrementally more positive on the outlook following yesterday's Q2 results.
10/02/18
10/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Goldman downgraded ConocoPhillips (COP) to Neutral following share outperformance with analyst Neil Mehta citing valuation. 2. U.S. Steel (X) and Reliance Steel (RS) were downgraded to Hold from Buy at Deutsche Bank. 3. Unilever (UN, UL) downgraded to Hold from Buy at Jefferies with analyst Martin Deboo saying the company is facing "choppier waters" and "higher expectations." 4. Ambev (ABEV) double downgraded to Sell from Buy at UBS with analyst Alan Alanis saying AmBev trades at a 25% higher valuation than parent company AB InBev (BUD), which is unwarranted. 5. Schlumberger (SLB) downgraded to Hold from Buy at Tudor Pickering. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BUD AB InBev
$85.58

-0.96 (-1.11%)

09/14/18
GUGG
09/14/18
INITIATION
Target $107
GUGG
Buy
AB InBev initiated with a Buy at Guggenheim
Guggenheim analyst Laurent Grandet initiated AB InBev with a Buy and $107 price target saying shares are undervalued relative to peers and believes concerns regarding US softness, Brazil volatility, and slower deleveraging are overdone.
09/13/18
GUGG
09/13/18
INITIATION
GUGG
Buy
AB InBev initiated with a Buy at Guggenheim
10/01/18
JEFF
10/01/18
DOWNGRADE
JEFF
Hold
AB InBev downgraded to Hold from Buy at Jefferies
Jefferies analyst Edward Mundy downgraded AB InBev to Hold and lowered his price target for the shares to EUR 80 from EUR 100. The company's external environment could be challenged as volatility in emerging markets puts pressure on earnings and input costs, Mundy tells investors in a research note. He sees a lack of positive catalysts for AB InBev shares.
CENX Century Aluminum
$11.84

-0.235 (-1.95%)

09/21/18
BREN
09/21/18
INITIATION
Target $10
BREN
Sell
Century Aluminum initiated with a Sell at Berenberg
Berenberg analyst Paretosh Misra initiated Century Aluminum with a $10 price target due to elevated alumina feedstock costs, where prices are up 50% year-to-date, pressuring earnings.
09/21/18
09/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Restaurant Brands (QSR) initiated with an Outperform at Baird. 2. FedEx (FDX) was initiated with a Buy at Berenberg while UPS (UPS) was initiated with a Hold. 3. Harmonic (HLIT) initiated with a Buy at Loop Capital. 4. TriplePoint Venture (TPVG) initiated with an Outperform at Wells Fargo. 5. Century Aluminum (CENX) initiated with a Sell at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $15
DBAB
Hold
Deutsche downgrades Century Aluminum on growing risks, reduced upside
Deutsche Bank analyst Jeremy Kliewer downgraded Century Aluminum to Hold from Buy and lowered his price target for the shares to $15 from $20. Century's margins could remain pressured for longer due to alumina supply disruptions, Kliewer tells investors in a research note. Further, the analyst feels little progress has been made with Santee Cooper, the electrical supplier at the company's Mt. Holly smelter, and that support for import tariffs may decline further following the November mid-term elections. As such, the analyst sees reduced upside potential and growing risk for Century Aluminum shares.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $15
DBAB
Hold
Century Aluminum downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Century Aluminum to Hold and lowered his price target for the shares to $15 from $20. The analyst sees growing risks and reduced upside potential at current share levels.
RS Reliance Steel
$85.21

-0.82 (-0.95%)

10/02/18
DBAB
10/02/18
NO CHANGE
DBAB
Deutsche downgrades Reliance, U.S. Steel on more cautious steel stance
To reflect a more cautious view on steel stocks, Deutsche Bank analyst Chris Terry downgraded both Reliance Steel (RS) and U.S. Steel (X) to Hold from Buy. The analyst says his view on the sector is "moderating post peak pricing." Most positive data points and catalysts have now largely played out, Terry tells investors in a research note. The analyst, however, keeps Buy ratings on Commercial Metals (CMC), Nucor (NUE) and Steel Dynamics (STLD) citing more favorable risk/reward profiles.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $90
DBAB
Hold
Reliance Steel downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Reliance Steel to Hold and lowered his price target for the shares to $90 from $100. The analyst says he's becoming more cautious on steel stocks.
09/17/18
09/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Reliance Steel (RS) initiated with a Neutral at Citi. 2. Bausch Health (BHC) assumed with an Overweight at Barclays. 3. Stanley Black & Decker (SWK) initiated with an Outperform at Credit Suisse. 4. Aramark (ARMK) initiated with an Outperform at Bernstein. 5. Kraft Heinz (KHC) was assumed with an Underweight at Morgan Stanley, while Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) were assumed with an Equal Weight. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
X U.S. Steel
$29.22

-1.02 (-3.37%)

09/27/18
LBOW
09/27/18
NO CHANGE
Target $49
LBOW
Buy
U.S. Steel estimates lowered on OCTG survey weakness at Longbow
Longbow analyst Chris Olin's latest sruvey of energy metal distributors and traders showed a deceleration in shipment growth reported by OCTG. Olin believes slowing end market demand growth, excess distribution inventories and modestly lower trending spot prices could ultimately limit Tubular Segment upside over the next 2-3 quarters, and when combined with negative momentum in carbon steel, puts $650M EBIT guidance at risk. The analyst lowered U.S. Steel's 2018 earnings forecast to $5.71 from $5.78, but maintains a Buy rating saying the company is positioned for continued earnings growth in 2019 as sheet/tube contracts stabilize at higher levels and US production moves towards 11-12M tons.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $35
DBAB
Hold
U.S. Steel downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded U.S. Steel to Hold and lowered his price target for the shares to $35 from $47. The analyst says he's becoming more cautious on steel stocks.
WTW Weight Watchers
$74.15

1.43 (1.97%)

09/13/18
09/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with an Equal Weight at Morgan Stanley. 2. AMSC (AMSC) initiated with a Buy at Craig-Hallum. 3. AudioEye (AEYE) initiated with a Buy at B. Riley FBR. 4. Lamar Advertising (LAMR) initiated with an Outperform at Imperial Capital. 5. Dicerna (DRNA) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/18
DADA
09/14/18
NO CHANGE
DADA
Neutral
Nutrisystem more likely than public peers to buy Jenny Craig, says DA Davidson
After The Wall Street Journal recently reported that private equity firm North Castle Partners is seeking a buyer of Jenny Craig, DA Davidson analyst Linda Bolton Weiser said she sees "zero probability" that Medifast (MED) would acquire it and "almost zero probability" that Weight Watchers (WTW) would buy the company. Nutrisystem (NTRI), however, has already shown an interest in adding non-cannibalizing brands to its portfolio, making it the most likely buyer of Jenny Craig among the publicly-traded weight loss companies Weiser covers, she stated. Nutrisystem, which seems to have hit a wall in growing its biggest brand, may need a bold strategic move to provide visibility on growth and expansion, added the analyst. She keeps Buy ratings on Medifast and Weight Watchers and a Neutral rating on Nutrisystem shares.
09/17/18
CHLM
09/17/18
NO CHANGE
Target $120
CHLM
Buy
Weight Watchers' refresh could be 'major' positive catalyst, says Craig-Hallum
Craig-Hallum analyst Alex Fuhrman reiterated a Buy rating and $120 price target on Weight Watchers. In a research note to investors, the analyst says he believes the upcoming Weight Watchers brand refresh, which is expected to be unveiled before the end of the year and possibly before the early-November Q3 report, could be a major positive catalyst for shares. Fuhrman says Weight Watchers' brick and mortar locations could be rebranded as "WW Studio," which he calls a "significant upgrade" from the current "meetings" offering and sees the likely renaming of the "OnlinePlus" offering and the corporate wellness offering. Additionally, Fuhrman expects that the company's "underutilized" B&M locations may be put to more use, including possibly introducing regular operating hours for some of its higher-traffic locations.
10/02/18
JPMS
10/02/18
NO CHANGE
Target $120
JPMS
Overweight
Weight Watchers added to America's Analyst Focus at JPMorgan
JPMorgan analyst Christina Brathwaite added Weight Watchers International to her firm's America's Analyst Focus while keeping an Overweight rating on the shares with a $120 price target. The stock's 30% pullback from its peak on June 20 presents a "compelling entry point for investors who missed the stock's appreciation the first time around," Brathwaite tells investors in a research note. Despite the post-earnings selloff, the analyst believes the Q2 print was actually indicative that Weight Watchers' growth story remains on track. Further, she believes the changes announced last week, including its new rewards program, as well as the company's Invite a Friend program, will help drive member recruitment and retention going forward.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
Morgan Stanley China hardware analyst to hold analyst/industry conference call »

China Hardware Tech…

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

BABA

Alibaba

$142.90

1.1 (0.78%)

, TCEHY

Tencent

$0.00

(0.00%)

12:17
10/20/18
10/20
12:17
10/20/18
12:17
Periodicals
Chinese internet giants down, not out, Barron's says »

Alibaba (BABA), Tencent…

BABA

Alibaba

$142.90

1.1 (0.78%)

TCEHY

Tencent

$0.00

(0.00%)

BIDU

Baidu

$191.93

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 02

    Nov

BLK

BlackRock

$401.61

1.74 (0.44%)

, IVZ

Invesco

$22.00

0.74 (3.48%)

12:13
10/20/18
10/20
12:13
10/20/18
12:13
Periodicals
Fund companies sued by own employees over pricey 401k plans, Barron's says »

BlackRock (BLK),…

BLK

BlackRock

$401.61

1.74 (0.44%)

IVZ

Invesco

$22.00

0.74 (3.48%)

TROW

T. Rowe Price

$100.13

0.31 (0.31%)

SCHW

Charles Schwab

$46.81

0.11 (0.24%)

MTB

M&T Bank

$162.72

2.09 (1.30%)

MS

Morgan Stanley

$46.43

0.4 (0.87%)

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

, BLK

BlackRock

$401.61

1.74 (0.44%)

12:04
10/20/18
10/20
12:04
10/20/18
12:04
Periodicals
Khashoggi case puts financial ties to Saudis under strain, Barron's says »

The suspected killing of…

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

BLK

BlackRock

$401.61

1.74 (0.44%)

BX

Blackstone

$34.66

-0.61 (-1.73%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

IMAX

Imax

$22.45

-0.11 (-0.49%)

SIX

Six Flags

$66.40

-1.16 (-1.72%)

WWE

WWE

$82.02

-1.49 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 13

    Nov

  • 14

    Nov

  • 26

    Feb

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.